Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe?
Life-threatening ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillation remain an ongoing clinical problem and their prevention and treatment require optimization. Conventional antiarrhythmic drugs are associated with significant proarrhythmic effects that often outwei...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/20/4732 |
| _version_ | 1797514273304346624 |
|---|---|
| author | Marta Oknińska Aleksandra Paterek Zuzanna Zambrowska Urszula Mackiewicz Michał Mączewski |
| author_facet | Marta Oknińska Aleksandra Paterek Zuzanna Zambrowska Urszula Mackiewicz Michał Mączewski |
| author_sort | Marta Oknińska |
| collection | DOAJ |
| description | Life-threatening ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillation remain an ongoing clinical problem and their prevention and treatment require optimization. Conventional antiarrhythmic drugs are associated with significant proarrhythmic effects that often outweigh their benefits. Another option, the implantable cardioverter defibrillator, though clearly the primary therapy for patients at high risk of ventricular arrhythmias, is costly, invasive, and requires regular monitoring. Thus there is a clear need for new antiarrhythmic treatment strategies. Ivabradine, a heartrate-reducing agent, an inhibitor of HCN channels, may be one of such options. In this review we discuss emerging data from experimental studies that indicate new mechanism of action of this drug and further areas of investigation and potential use of ivabradine as an antiarrhythmic agent. However, clinical evidence is limited, and the jury is still out on effects of ivabradine on cardiac ventricular arrhythmias in the clinical setting. |
| first_indexed | 2024-03-10T06:29:17Z |
| format | Article |
| id | doaj.art-d9e7388e12ab4ad48e899a0d3e142699 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T06:29:17Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-d9e7388e12ab4ad48e899a0d3e1426992023-11-22T18:42:21ZengMDPI AGJournal of Clinical Medicine2077-03832021-10-011020473210.3390/jcm10204732Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe?Marta Oknińska0Aleksandra Paterek1Zuzanna Zambrowska2Urszula Mackiewicz3Michał Mączewski4Centre of Postgraduate Medical Education, Department of Clinical Physiology, ul. Marymoncka 99/103, 01-813 Warsaw, PolandCentre of Postgraduate Medical Education, Department of Clinical Physiology, ul. Marymoncka 99/103, 01-813 Warsaw, PolandCentre of Postgraduate Medical Education, Department of Clinical Physiology, ul. Marymoncka 99/103, 01-813 Warsaw, PolandCentre of Postgraduate Medical Education, Department of Clinical Physiology, ul. Marymoncka 99/103, 01-813 Warsaw, PolandCentre of Postgraduate Medical Education, Department of Clinical Physiology, ul. Marymoncka 99/103, 01-813 Warsaw, PolandLife-threatening ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillation remain an ongoing clinical problem and their prevention and treatment require optimization. Conventional antiarrhythmic drugs are associated with significant proarrhythmic effects that often outweigh their benefits. Another option, the implantable cardioverter defibrillator, though clearly the primary therapy for patients at high risk of ventricular arrhythmias, is costly, invasive, and requires regular monitoring. Thus there is a clear need for new antiarrhythmic treatment strategies. Ivabradine, a heartrate-reducing agent, an inhibitor of HCN channels, may be one of such options. In this review we discuss emerging data from experimental studies that indicate new mechanism of action of this drug and further areas of investigation and potential use of ivabradine as an antiarrhythmic agent. However, clinical evidence is limited, and the jury is still out on effects of ivabradine on cardiac ventricular arrhythmias in the clinical setting.https://www.mdpi.com/2077-0383/10/20/4732ivabradineHCN channelsheart failurecoronary artery diseaseventricular arrhythmiasventricular tachycardia |
| spellingShingle | Marta Oknińska Aleksandra Paterek Zuzanna Zambrowska Urszula Mackiewicz Michał Mączewski Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe? Journal of Clinical Medicine ivabradine HCN channels heart failure coronary artery disease ventricular arrhythmias ventricular tachycardia |
| title | Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe? |
| title_full | Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe? |
| title_fullStr | Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe? |
| title_full_unstemmed | Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe? |
| title_short | Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe? |
| title_sort | effect of ivabradine on cardiac ventricular arrhythmias friend or foe |
| topic | ivabradine HCN channels heart failure coronary artery disease ventricular arrhythmias ventricular tachycardia |
| url | https://www.mdpi.com/2077-0383/10/20/4732 |
| work_keys_str_mv | AT martaokninska effectofivabradineoncardiacventriculararrhythmiasfriendorfoe AT aleksandrapaterek effectofivabradineoncardiacventriculararrhythmiasfriendorfoe AT zuzannazambrowska effectofivabradineoncardiacventriculararrhythmiasfriendorfoe AT urszulamackiewicz effectofivabradineoncardiacventriculararrhythmiasfriendorfoe AT michałmaczewski effectofivabradineoncardiacventriculararrhythmiasfriendorfoe |